Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rosana Ely Nakamura is active.

Publication


Featured researches published by Rosana Ely Nakamura.


JAMA | 2010

Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial.

Ludhmila Abrahão Hajjar; Jean Louis Vincent; Filomena Regina Barbosa Gomes Galas; Rosana Ely Nakamura; Carolina Silva; Marília Harumi Higuchi dos Santos; J Fukushima; Roberto Kalil Filho; Denise B. Sierra; Neuza Lopes; Thais Mauad; A Roquim; M Sundin; Wanderson C Leão; José Paulo Almeida; Pablo Maria Alberto Pomerantzeff; Luis Oliveira Dallan; Fabio Biscegli Jatene; Noedir A. G Stolf; José Otávio Costa Auler

CONTEXT Perioperative red blood cell transfusion is commonly used to address anemia, an independent risk factor for morbidity and mortality after cardiac operations; however, evidence regarding optimal blood transfusion practice in patients undergoing cardiac surgery is lacking. OBJECTIVE To define whether a restrictive perioperative red blood cell transfusion strategy is as safe as a liberal strategy in patients undergoing elective cardiac surgery. DESIGN, SETTING, AND PATIENTS The Transfusion Requirements After Cardiac Surgery (TRACS) study, a prospective, randomized, controlled clinical noninferiority trial conducted between February 2009 and February 2010 in an intensive care unit at a university hospital cardiac surgery referral center in Brazil. Consecutive adult patients (n = 502) who underwent cardiac surgery with cardiopulmonary bypass were eligible; analysis was by intention-to-treat. INTERVENTION Patients were randomly assigned to a liberal strategy of blood transfusion (to maintain a hematocrit ≥30%) or to a restrictive strategy (hematocrit ≥24%). MAIN OUTCOME MEASURE Composite end point of 30-day all-cause mortality and severe morbidity (cardiogenic shock, acute respiratory distress syndrome, or acute renal injury requiring dialysis or hemofiltration) occurring during the hospital stay. The noninferiority margin was predefined at -8% (ie, 8% minimal clinically important increase in occurrence of the composite end point). RESULTS Hemoglobin concentrations were maintained at a mean of 10.5 g/dL (95% confidence interval [CI], 10.4-10.6) in the liberal-strategy group and 9.1 g/dL (95% CI, 9.0-9.2) in the restrictive-strategy group (P < .001). A total of 198 of 253 patients (78%) in the liberal-strategy group and 118 of 249 (47%) in the restrictive-strategy group received a blood transfusion (P < .001). Occurrence of the primary end point was similar between groups (10% liberal vs 11% restrictive; between-group difference, 1% [95% CI, -6% to 4%]; P = .85). Independent of transfusion strategy, the number of transfused red blood cell units was an independent risk factor for clinical complications or death at 30 days (hazard ratio for each additional unit transfused, 1.2 [95% CI, 1.1-1.4]; P = .002). CONCLUSION Among patients undergoing cardiac surgery, the use of a restrictive perioperative transfusion strategy compared with a more liberal strategy resulted in noninferior rates of the combined outcome of 30-day all-cause mortality and severe morbidity. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01021631.


Anesthesiology | 2015

Transfusion Requirements in Surgical Oncology Patients A Prospective, Randomized Controlled Trial

Juliano Pinheiro de Almeida; Jean Louis Vincent; Filomena Regina Barbosa Gomes Galas; Elisangela Pinto Marinho de Almeida; J Fukushima; E Osawa; F Bergamin; C Park; Rosana Ely Nakamura; Silvia Moulin Ribeiro Fonseca; Guilherme Cutait; Joseane Inacio Alves; Mellik Bazan; Silvia Vieira; Ana C. Vieira Sandrini; Henrique Palomba; Ulysses Ribeiro; Alexandre Crippa; Marcos F. Dall'Oglio; Maria Del Pilar Estevez Diz; Roberto Kalil Filho; José Otávio Costa Auler; Andrew Rhodes; Ludhmila Abrahão Hajjar

Background:Several studies have indicated that a restrictive erythrocyte transfusion strategy is as safe as a liberal one in critically ill patients, but there is no clear evidence to support the superiority of any perioperative transfusion strategy in patients with cancer. Methods:In a randomized, controlled, parallel-group, double-blind (patients and outcome assessors) superiority trial in the intensive care unit of a tertiary oncology hospital, the authors evaluated whether a restrictive strategy of erythrocyte transfusion (transfusion when hemoglobin concentration <7 g/dl) was superior to a liberal one (transfusion when hemoglobin concentration <9 g/dl) for reducing mortality and severe clinical complications among patients having major cancer surgery. All adult patients with cancer having major abdominal surgery who required postoperative intensive care were included and randomly allocated to treatment with the liberal or the restrictive erythrocyte transfusion strategy. The primary outcome was a composite endpoint of mortality and morbidity. Results:A total of 198 patients were included as follows: 101 in the restrictive group and 97 in the liberal group. The primary composite endpoint occurred in 19.6% (95% CI, 12.9 to 28.6%) of patients in the liberal-strategy group and in 35.6% (27.0 to 45.4%) of patients in the restrictive-strategy group (P = 0.012). Compared with the restrictive strategy, the liberal transfusion strategy was associated with an absolute risk reduction for the composite outcome of 16% (3.8 to 28.2%) and a number needed to treat of 6.2 (3.5 to 26.5). Conclusion:A liberal erythrocyte transfusion strategy with a hemoglobin trigger of 9 g/dl was associated with fewer major postoperative complications in patients having major cancer surgery compared with a restrictive strategy.


Critical Care Medicine | 2015

Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review.

E Osawa; Andrew Rhodes; Giovanni Landoni; Filomena Regina Barbosa Gomes Galas; J Fukushima; C Park; Juliano Pinheiro de Almeida; Rosana Ely Nakamura; Tania Mara Varejao Strabelli; Brunna Pileggi; A Leme; Evgeny Fominskiy; Yasser Sakr; Marta Fernandes Lima; Rafael Alves Franco; Raquel Pei Chen Chan; Marilde de Albuquerque Piccioni; Priscilla de Brito Nunes Mendes; Suéllen R. Menezes; Tatiana Cristina Bruno; Fábio Antônio Gaiotto; Luiz Augusto Ferreira Lisboa; Luiz Alberto de Oliveira Dallan; Alexandre Ciappina Hueb; Pablo Maria Alberto Pomerantzeff; Roberto Kalil Filho; Fabio Biscegli Jatene; José Otávio Costa Auler Júnior; Ludhmila Abrahão Hajjar

Objectives:To evaluate the effects of goal-directed therapy on outcomes in high-risk patients undergoing cardiac surgery. Design:A prospective randomized controlled trial and an updated metaanalysis of randomized trials published from inception up to May 1, 2015. Setting:Surgical ICU within a tertiary referral university-affiliated teaching hospital. Patients:One hundred twenty-six high-risk patients undergoing coronary artery bypass surgery or valve repair. Interventions:Patients were randomized to a cardiac output–guided hemodynamic therapy algorithm (goal-directed therapy group, n = 62) or to usual care (n = 64). In the goal-directed therapy arm, a cardiac index of greater than 3 L/min/m2 was targeted with IV fluids, inotropes, and RBC transfusion starting from cardiopulmonary bypass and ending 8 hours after arrival to the ICU. Measurements and Main Results:The primary outcome was a composite endpoint of 30-day mortality and major postoperative complications. Patients from the goal-directed therapy group received a greater median (interquartile range) volume of IV fluids than the usual care group (1,000 [625–1,500] vs 500 [500–1,000] mL; p < 0.001], with no differences in the administration of either inotropes or RBC transfusions. The primary outcome was reduced in the goal-directed therapy group (27.4% vs 45.3%; p = 0.037). The goal-directed therapy group had a lower occurrence rate of infection (12.9% vs 29.7%; p = 0.002) and low cardiac output syndrome (6.5% vs 26.6%; p = 0.002). We also observed lower ICU cumulative dosage of dobutamine (12 vs 19 mg/kg; p = 0.003) and a shorter ICU (3 [3–4] vs 5 [4–7] d; p < 0.001) and hospital length of stay (9 [8–16] vs 12 [9–22] d; p = 0.049) in the goal-directed therapy compared with the usual care group. There were no differences in 30-day mortality rates (4.8% vs 9.4%, respectively; p = 0.492). The metaanalysis identified six trials and showed that, when compared with standard treatment, goal-directed therapy reduced the overall rate of complications (goal-directed therapy, 47/410 [11%] vs usual care, 92/415 [22%]; odds ratio, 0.40 [95% CI, 0.26–0.63]; p < 0.0001) and decreased the hospital length of stay (mean difference, –5.44 d; 95% CI, –9.28 to –1.60; p = 0.006) with no difference in postoperative mortality: 9 of 410 (2.2%) versus 15 of 415 (3.6%), odds ratio, 0.61 (95% CI, 0.26–1.47), and p = 0.27. Conclusions:Goal-directed therapy using fluids, inotropes, and blood transfusion reduced 30-day major complications in high-risk patients undergoing cardiac surgery.


Anesthesiology | 2017

Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock After Cardiac Surgery: The VANCS Randomized Controlled Trial.

Ludhmila Abrahão Hajjar; Jean Louis Vincent; Filomena Regina Barbosa Gomes Galas; Andrew Rhodes; Giovanni Landoni; E Osawa; Renato Rosa Melo; M Sundin; Solimar Miranda Grande; Fábio Antônio Gaiotto; Pablo Maria Alberto Pomerantzeff; Luis Oliveira Dallan; Rafael Alves Franco; Rosana Ely Nakamura; Luiz Augusto Ferreira Lisboa; Juliano Pinheiro de Almeida; Aline Muller Gerent; Dayenne Hianae Souza; Maria Alice Gaiane; J Fukushima; C Park; Cristiane Zambolim; Graziela Santos Rocha Ferreira; Tânia Mara Varejão Strabelli; Felipe Lourenço Fernandes; L Camara; S Zeferino; Valter Garcia Santos; Marilde de Albuquerque Piccioni; Fabio Biscegli Jatene

Background: Vasoplegic syndrome is a common complication after cardiac surgery and impacts negatively on patient outcomes. The objective of this study was to evaluate whether vasopressin is superior to norepinephrine in reducing postoperative complications in patients with vasoplegic syndrome. Methods: This prospective, randomized, double-blind trial was conducted at the Heart Institute, University of Sao Paulo, Sao Paulo, Brazil, between January 2012 and March 2014. Patients with vasoplegic shock (defined as mean arterial pressure less than 65 mmHg resistant to fluid challenge and cardiac index greater than 2.2 l · min−1 · m−2) after cardiac surgery were randomized to receive vasopressin (0.01 to 0.06 U/min) or norepinephrine (10 to 60 &mgr;g/min) to maintain arterial pressure. The primary endpoint was a composite of mortality or severe complications (stroke, requirement for mechanical ventilation for longer than 48 h, deep sternal wound infection, reoperation, or acute renal failure) within 30 days. Results: A total of 330 patients were randomized, and 300 were infused with one of the study drugs (vasopressin, 149; norepinephrine, 151). The primary outcome occurred in 32% of the vasopressin patients and in 49% of the norepinephrine patients (unadjusted hazard ratio, 0.55; 95% CI, 0.38 to 0.80; P = 0.0014). Regarding adverse events, the authors found a lower occurrence of atrial fibrillation in the vasopressin group (63.8% vs. 82.1%; P = 0.0004) and no difference between groups in the rates of digital ischemia, mesenteric ischemia, hyponatremia, and myocardial infarction. Conclusions: The authors’ results suggest that vasopressin can be used as a first-line vasopressor agent in postcardiac surgery vasoplegic shock and improves clinical outcomes.


Revista Brasileira De Anestesiologia | 2013

Volume replacement therapy during hip arthroplasty using hydroxyethyl starch (130/0.4) compared to lactated Ringer decreases allogeneic blood transfusion and postoperative infection

Adilson Hamaji; Ludhmila Abrahão Hajjar; Marcelo Tadeu Caiero; Juliano Pinheiro de Almeida; Rosana Ely Nakamura; E Osawa; J Fukushima; Filomena Regina Barbosa Gomes Galas; José Otávio Costa Auler Júnior

BACKGROUND AND OBJECTIVES Hydroxyethyl starch (HES) 130/0.4 is considered an effective plasma expander when compared to crystalloids. There is controversy around its superiority regarding hemodynamic optimization and about possible detrimental effects on coagulation. The aim of this study was to compare the effects of HES 130/0.4 to lactated Ringer solution during hip arthroplasty in adult patients under spinal anesthesia regarding intraoperative bleeding, hemodynamic parameters, coagulation profile, transfusion requirements and clinical outcomes. METHODS In this randomized, controlled trial, 48 patients scheduled for hip arthroplasty with spinal anesthesia were randomized into two groups: 24 patients were allocated to receive a preload of 15 mL.kg(-1) of HES 130/0.4 and 24 patients received a preload of 30 mL.kg(-1) lactated Ringer solution before surgery. Hemodynamic measurements, hemoglobin concentrations, biochemical parameters and coagulation tests were evaluated in three periods during surgical procedure. Patients received medical follow-up during their hospital stay and up to postoperative 30 days. Primary outcome was the requirement of red blood cell transfusion between groups during hospital stay. Secondary outcome were hemodynamic parameters, length of hospital stay, mortality and occurrence of clinical postoperative complications. RESULTS Red blood cell transfusion was required in 17% of patients in the HES group and in 46% in the Ringer group (p = .029). Postoperative infections were more frequently observed in the Ringer group (17%) compared to the HES group (0), p = .037. There were no significant differences between groups in mortality, hospital length of stay and clinical complications other than infection. CONCLUSIONS During hip arthroplasty, patients treated with hypervolemic hemodilution with hydroxyethyl starch 130/0.4 required less transfusion and presented lower infection rate compared to patients who received lactated Ringer.


Critical Care Medicine | 2017

Liberal Versus Restrictive Transfusion Strategy in Critically Ill Oncologic Patients: The Transfusion Requirements in Critically Ill Oncologic Patients Randomized Controlled Trial*

F Bergamin; Juliano Pinheiro de Almeida; Giovanni Landoni; Filomena Regina Barbosa Gomes Galas; J Fukushima; Evgeny Fominskiy; C Park; E Osawa; Maria Del Pilar Estevez Diz; Gisele Queiroz de Oliveira; Rafael Alves Franco; Rosana Ely Nakamura; Elisangela Pinto Marinho de Almeida; Edson Abdala; Maristela Pinheiro Freire; Roberto Kalil Filho; José Otávio Costa Auler; Ludhmila Abrahão Hajjar

Objective: To assess whether a restrictive strategy of RBC transfusion reduces 28-day mortality when compared with a liberal strategy in cancer patients with septic shock. Design: Single center, randomized, double-blind controlled trial. Setting: Teaching hospital. Patients: Adult cancer patients with septic shock in the first 6 hours of ICU admission. Interventions: Patients were randomized to the liberal (hemoglobin threshold, < 9 g/dL) or to the restrictive strategy (hemoglobin threshold, < 7 g/dL) of RBC transfusion during ICU stay. Measurements and Main Results: Patients were randomized to the liberal (n = 149) or to the restrictive transfusion strategy (n = 151) group. Patients in the liberal group received more RBC units than patients in the restrictive group (1 [0–3] vs 0 [0–2] unit; p < 0.001). At 28 days after randomization, mortality rate in the liberal group (primary endpoint of the study) was 45% (67 patients) versus 56% (84 patients) in the restrictive group (hazard ratio, 0.74; 95% CI, 0.53–1.04; p = 0.08) with no differences in ICU and hospital length of stay. At 90 days after randomization, mortality rate in the liberal group was lower (59% vs 70%) than in the restrictive group (hazard ratio, 0.72; 95% CI, 0.53–0.97; p = 0.03). Conclusions: We observed a survival trend favoring a liberal transfusion strategy in patients with septic shock when compared with the restrictive strategy. These results went in the opposite direction of the a priori hypothesis and of other trials in the field and need to be confirmed.


Revista Brasileira De Anestesiologia | 2013

Bronchial injury and pneumothorax after reintubation using an airway exchange catheter.

Juliano Pinheiro de Almeida; Ludhmila Abrahão Hajjar; J Fukushima; Rosana Ely Nakamura; Rodolfo Albertini; Filomena Regina Barbosa Gomes Galas

BACKGROUND AND OBJECTIVES We report a case of pneumothorax caused by a bronchial perforation during a reintubation using an airway exchange catheter (AEC) in a patient with a head and neck cancer. CASE REPORT A 53 year old man with oropharynx carcinoma was admitted to ICU for severe pneumonia and severe acute respiratory distress syndrome (ARDS). The patient was recognized as a difficult-to-intubate patient and an endotracheal tube (ETT) was inserted through a bronchoscope. After one week of treatment, it was observed an endotracheal cuff perforation. Exchanging the endotracheal tube was necessary to achieve satisfactory pulmonary ventilation. An AEC Cook 14 was used to perform the reintubation. After reintubation, the patient presented a worsening in oxygen saturation and a chest radiography (CXR) revealed a large pneumothorax. A chest tube was inserted and we observed immediate improvement in oxygen saturation. A repeat CXR confirmed correct positioning of the chest tube and reexpansion of the right lung. A bronchoscopy performed showed a posterior laceration in the right main bronchus. The patient was extubated the following day. After four days, the chest tube was removed. A CXR performed a day after chest tube removal revealed a small right upper pneumothorax, but the patient remained asymptomatic. CONCLUSIONS Airway exchange catheter is a valuable tool to handle with difficult-to-intubate patients. Although the physicians generally focus their attention in avoid barotrauma - caused by oxygen supplement or jet ventilation through AEC - concern for insertion technique can minimize life threatening complications and increase the safety of AEC.


Critical Care | 2010

Impact of positive fluid balance on survival in critically ill cancer patients

Juliano J.P. Almeida; H Palomba; L Hajjar; V Torres; F Galas; Fa Duarte; D Nagaoka; Rosana Ely Nakamura; J Fukushima; L Yu

Fluid overload has recently been linked to adverse outcomes in critically ill patients, but its impact on the outcomes of cancer patients admitted to intensive care units (ICUs) has not been previously described.


Anesthesiology | 2017

Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery

Ludhmila Abrahão Hajjar; Fábio Antônio Gaiotto; Pablo Maria Alberto Pomerantzeff; Luis Oliveira Dallan; Rafael Alves Franco; Rosana Ely Nakamura; Luiz Augusto Ferreira Lisboa; Juliano Pinheiro de Almeida; Aline Muller Gerent; Dayenne Hianae Souza; Maria Alice Gaiane; Jean Louis Vincent; J Fukushima; C Park; Cristiane Zambolim; Graziela Santos Rocha Ferreira; Tânia Mara Varejão Strabelli; Felipe Lourenço Fernandes; L Camara; S Zeferino; Valter Garcia Santos; Marilde de Albuquerque Piccioni; Filomena Regina Barbosa Gomes Galas; Fabio Biscegli Jatene; José Otávio Costa Auler; Roberto Kalil Filho; Andrew Rhodes; Giovanni Landoni; E Osawa; Renato Rosa Melo

Background: Vasoplegic syndrome is a common complication after cardiac surgery and impacts negatively on patient outcomes. The objective of this study was to evaluate whether vasopressin is superior to norepinephrine in reducing postoperative complications in patients with vasoplegic syndrome. Methods: This prospective, randomized, double-blind trial was conducted at the Heart Institute, University of Sao Paulo, Sao Paulo, Brazil, between January 2012 and March 2014. Patients with vasoplegic shock (defined as mean arterial pressure less than 65 mmHg resistant to fluid challenge and cardiac index greater than 2.2 l · min−1 · m−2) after cardiac surgery were randomized to receive vasopressin (0.01 to 0.06 U/min) or norepinephrine (10 to 60 &mgr;g/min) to maintain arterial pressure. The primary endpoint was a composite of mortality or severe complications (stroke, requirement for mechanical ventilation for longer than 48 h, deep sternal wound infection, reoperation, or acute renal failure) within 30 days. Results: A total of 330 patients were randomized, and 300 were infused with one of the study drugs (vasopressin, 149; norepinephrine, 151). The primary outcome occurred in 32% of the vasopressin patients and in 49% of the norepinephrine patients (unadjusted hazard ratio, 0.55; 95% CI, 0.38 to 0.80; P = 0.0014). Regarding adverse events, the authors found a lower occurrence of atrial fibrillation in the vasopressin group (63.8% vs. 82.1%; P = 0.0004) and no difference between groups in the rates of digital ischemia, mesenteric ischemia, hyponatremia, and myocardial infarction. Conclusions: The authors’ results suggest that vasopressin can be used as a first-line vasopressor agent in postcardiac surgery vasoplegic shock and improves clinical outcomes.


Revista Brasileira De Anestesiologia | 2013

Terapia de reposição volêmica durante artroplastia de quadril usando hidroxietilamido (130/0,4) comparado com Ringer lactato diminui transfusão de sangue alogênico e infecção pós-operatória

Adilson Hamaji; Ludhmila Abrahão Hajjar; Marcelo Tadeu Caiero; Juliano Pinheiro de Almeida; Rosana Ely Nakamura; E Osawa; J Fukushima; Filomena Regina Barbosa Gomes Galas; José Otávio Costa Auler Júnior

JUSTIFICATIVA Y OBJETIVOS: El hidroxietilalmidon 130/0,4 (HES 130/0,4) esta considerado como un expansivo plasmatico efectivo cuando se le compara con los cristaloides. Existen controversias sobre su superioridad con relacion a la optimizacion hemodinamica y sobre posibles efectos perjudiciales en la coagulacion. El objetivo de este estudio, fue comparar los efectos del HES 130/0,4 con los de la solucion de lactato de Ringer durante la artroplastia de cadera en pacientes adultos bajo raquianestesia, considerando el sangramiento intraoperatorio, los parametros hemodinamicos, el coagulograma, la necesidad de transfusion y los resultados clinicos. METODOS: En este estudio aleatorio y controlado, 48 pacientes citados para la artroplastia de cadera con raquianestesia fueron aleatoriamente divididos en dos grupos: 24 pacientes fueron ubicados para recibir una pre-carga de HES 130/0,4 (15 mL.kg-1) y 24 pacientes recibieron una pre-carga de solucion de lactato de Ringer (30 mL.kg-1) antes de la cirugia. Las medidas hemodinamicas, concentracion de hemoglobina, parametros bioquimicos y los test de coagulacion fueron evaluados en tres periodos durante el procedimiento quirurgico. Los pacientes recibieron un acompanamiento medico durante el ingreso y de 30 dias en el periodo del postoperatorio. El principal factor fue la necesidad de transfusion de hematies entre los grupos durante el ingreso. Los factores secundarios fueron los parametros hemodinamicos, tiempo de ingreso, mortalidad y aparecimiento de complicaciones clinicas. RESULTADOS: La transfusion de hematies fue necesaria en un 17% de los pacientes del grupo HES y en un 46% de los pacientes del grupo lactato de Ringer (p = 0,029). Las infecciones postoperatorias fueron observadas con mas frecuencia en el grupo lactato de Ringer (17%) en comparacion con el grupo HES (0), p = 0,037. No hubo diferencias significativas entre los grupos con relacion a la mortalidad, tiempo de ingreso y complicaciones clinicas, excepto en la infeccion. Conclusiones: Durante la artroplastia de cadera, los pacientes tratados con hemodilucion hipervolemica normal con hidroxietilalmidon 130/0.4 necesitaron menos transfusion y presentaron un indice menor de infeccion en comparacion con los pacientes que recibieron lactato de Ringer.

Collaboration


Dive into the Rosana Ely Nakamura's collaboration.

Top Co-Authors

Avatar

J Fukushima

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

E Osawa

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C Park

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

F Galas

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

L Hajjar

University of São Paulo

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge